Hepatiq, Inc.

Irvine,  CA 
United States
http://www.hepatiq.com
  • Booth: 1071


HEPATIQ for quantitative liver function.

HEPATIQ is the first automated software to provide quantitative liver function (PHM) using nuclear medicine.  Other tests on the market estimate liver fibrosis (or scarring) and do not quantitate liver function.  HEPATIQ also provides liver and spleen volumes (fLV and fSV) which aid in differential diagnosis.

Scarring damage can be mitigated by increased blood flow and generation of new functioning lobules.  Patient outcomes are determined by the residual liver function, not the extent of scarring.  This was shown in the HALT-C trial which concluded that quantitative liver function “… may be superior to histological staging by liver biopsy in identifying both high- and low-risk groups and may be more accurate than staging fibrosis in predicting clinical outcomes”.

Baseline PHM was significantly lower and fSV significantly larger in HALT-C patients who experienced outcomes including variceal bleeding, ascites, hepatic encephalopathy, and liver-related death.  This trial also showed that Ishak fibrosis stage dropped from significance in the prediction of clinical outcomes in models that included PHM or fSV. 

HEPATIQ has been cleared by the FDA.  More information at www.hepatiq.com.

Brands: HEPATIQ provides quantitative liver function (PHM), liver and spleen volumes (fLV/fSV) which aid in the diagnosis, staging and management of liver disease. HEPATIQ is FDA cleared. www.hepatiq.com.


 Products

  • HEPATIQ - Quantitative Liver Function
    Infections, alcohol and fat buildup reduce liver function. HEPATIQ is the first automated software to quantitate liver function using nuclear medicine. Other tests estimate fibrosis (or scarring) in the liver and do not quantitate liver function.

    ...

  • Quantitative Liver Function

    Liver function can be reduced by infections, alcohol and fat buildup.  HEPATIQ is the first automated software to precisely provide quantitative liver function using nuclear medicine.  Other tests on the market estimate the extent of fibrosis (or scarring) in the liver and do not quantitate liver function.

    Function Determines Outcomes

    The liver can generate new functioning lobules thus mitigating some of the scarring damage.  Blood flow to the liver may also increase to further compensate for the damage.  What determines patient outcomes is the residual amount of liver function, not the extent of scarring.  This was shown in the National Institutes of Health sponsored HALT-C trial which concluded that quantitative liver function “… may be superior to histological staging by liver biopsy in identifying both high- and low-risk groups and may be more accurate than staging fibrosis in predicting clinical outcomes”.

    FDA Cleared

    HEPATIQ is cleared for sale by the Food and Drug Administration.  It provides 3 indices of liver disease that permit differential diagnoses not possible with one dimensional tests.

    1. PHM (perfused hepatic mass):      Quantitates liver function.
    2. fSV (functional spleen volume):    Indicator of portal hypertension.
    3. fLV (functional liver volume):        Indicator of fatty liver disease.

    Better Patient Management

    The 8 year HALT-C trial showed that baseline PHM was significantly lower and fSV significantly larger in patients who subsequently experienced clinical outcomes including variceal bleeding, ascites, hepatic encephalopathy, and liver-related death.  This trial also showed that Ishak fibrosis stage dropped from significance in the prediction of clinical outcomes in models that included PHM or fSV.  Perhaps even more important, characterization of a patient as low risk by quantitative liver function was associated with a very low risk for adverse clinical outcome. PHM and fLV were also shown to precisely track liver function and volume regeneration after an adult-to-adult live donor liver transplant in the A2ALL study. 

For Technical Support with this webpage, please contact support.